HV Capital and Unbound led a $15m Series B round in Bioniq.

HV Capital, a venture capital firm, and Unbound led a $15m Series B round in Bioniq, a provider of personalized supplements based on blood biomarker data. “Everyone’s health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users,” Vadim Fedotov, Bioniq CEO.